Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I
Hematology Disease Topics & Pathways:
Research, Assays, Translational Research, Emerging technologies, Technology and Procedures
We developed a T-cell specific dPCR assay that can be multiplexed with CAR-T and control gene dPCR assays to provide quantitation of CAR-T cells, total T-cells, and total nucleated cells. This assay eliminates the need for redundant quantitation of T-cells by flow cytometry and in combination with ultra-sensitive CAR-T dPCR assays can allow a greater depth of CAR-T quantitation relative to total T cells with minimal source sample needs. The assay is built around the T-cell receptor excision circle (TREC) locus within the T-cell receptor alpha (TCRa) gene, such that the dPCR amplicon is only present in TCRa germline or non-T cells. The percentage of T-cells can then be calculated relative to the total nucleated cells in the sample.
This TCRa dPCR assay (VIC fluorophore) was developed to be multiplexed with customized CAR-specific dPCR assays (FAM fluorophore) and with an albumin reference gene (Cy5 fluorophore) on a Qiagen Qiacuity dPCR instrument. We validated the assay using the T-cell line Jurkat and the AML cell line MOLM13 in serial dilutions, as well as in bulk mononuclear cells and T-cell enriched peripheral blood samples from healthy donors (Pearson correlation coefficients, r, ranging 0.86-0.99). We then confirmed strong correlation between flow cytometry assessments of T-cell quantity and TCRa assay-based T-cell quantitation in banked peripheral blood samples from patients treated with the CAR-T construct UCD19 (r=0.95)(NCT05535855); these latter experiments also confirmed multiplexing capability with the UCD19 CAR-specific assay (r=0.99 between our analysis and the trial dPCR analysis).
In summary, the TCRa dPCR assay allows quantitation of CAR+ T-cells relative to total T-cells and total nucleated cells in patient samples in a single multiplexed assay without requiring additional clinical sample usage.
Disclosures: Murphy: Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Fry: United States Patent and Trademark Office: Patents & Royalties: WO2015084513A1; United States Patent and Trademark Office: Patents & Royalties: WO2019178382A1; Sana Biotechnology: Consultancy, Current equity holder in publicly-traded company, Ended employment in the past 24 months; United States Patent and Trademark Office: Patents & Royalties: WO2017205747A1.